Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) are entero-pancreatic hormone-based treatments first approved in 2005 for type 2 diabetes (T2D). They are now commonly prescribed for weight ...
Looking at the data from clinical trials of new GLP-1 agonists, it's clear that patients will need to stay on the drugs to maintain their weight loss, experts said. At the same time, there's a ...